CONNECTA Therapeutics Initiates Phase IIa Clinical Trial of CTH120, a First-in-Class Neuroplasticity Modulator, in Fragile X Syndrome

CONNECTA Therapeutics Initiates Phase IIa Clinical Trial of CTH120, a First-in-Class Neuroplasticity Modulator, in Fragile X Syndrome

Builds on positive Phase I safety data and represents a key value-inflection milestone for the CompanyAdvances a

CONNECTA Therapeutics begins Phase IIa trial of CTH120 for FXS

CONNECTA Therapeutics has started a Phase IIa trial to assess CTH120, a neuroplasticity modulator, in adult males with fragile X syndrome.The post CONNECTA Therapeutics begins Phase IIa trial of CTH120 for FXS appeared first on Hospital Management.

Connecta launches phase 2a trial of neuroplasticity modulator

Study marks major milestone for CTH120 as company advances disease‑modifying ambitions